ICICI Prudential Mutual Fund decreased its stake in Cipla Limited from 2.40% to 2.36%, with its shareholding moving from 19,324,659 to 18,982,812 shares. While the current transaction details do not specify a value, ICICI Prudential Mutual Fund previously purchased over 55 lakh shares (0.68% stake) for ₹743 crore at ₹1345 per share in a block deal on May 15, 2024.
A leading pharmaceutical manufacturer, Cipla develops and markets branded and generic formulations alongside active pharmaceutical ingredients across multiple therapeutic areas. Established in 1935, the company operates manufacturing facilities across India and internationally, serving both domestic and global markets. Cipla's distinctive strength lies in its integrated business model combining formulation development with API production, enabling cost-efficient drug manufacturing, distribution, and accessibility to patients worldwide.
India's second-largest AMC by AUM with over Rs 9 lakh crore managed across 80+ schemes. Joint venture between ICICI Bank and Prudential plc. CIO S. Naren is one of India's most recognised value investors, known for contrarian macro calls and rotating across market caps well ahead of consensus. ICICI Pru's quarterly portfolio disclosures are among the most closely watched in the industry.
